All‐cause mortality (7 days ‐ 3 months) · people aged ≥ 18 years with a diagnosis of new or recurrent VTE
Subcutaneous unfractionated heparin showed no clear difference in all‐cause mortality (7 days ‐ 3 months) compared with low molecular weight heparin (low certainty).
1 finding from 1 review
Asymptomatic VTE at 3 months · people aged ≥ 18 years with a diagnosis of new or recurrent VTE
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Symptomatic recurrent DVT at 3 months · people aged ≥ 18 years with a diagnosis of new or recurrent VTE
Subcutaneous unfractionated heparin showed no clear difference in symptomatic recurrent DVT at 3 months compared with intravenous unfractionated heparin (low certainty).
1 finding from 1 review
PE at 3 months · people aged ≥ 18 years with a diagnosis of new or recurrent VTE
Subcutaneous unfractionated heparin showed no clear difference in PE at 3 months compared with intravenous unfractionated heparin (low certainty).
1 finding from 1 review
VTE‐related mortality4 · people aged ≥ 18 years with a diagnosis of new or recurrent VTE
Subcutaneous unfractionated heparin showed no clear difference in VTE‐related mortality at 3 months compared with intravenous unfractionated heparin (low certainty).
1 finding from 1 review
Major bleedingd (3 months) · people aged ≥ 18 years with a diagnosis of new or recurrent VTE
Subcutaneous unfractionated heparin showed no clear difference in major bleedingd (7 days ‐ 12 months) compared with intravenous unfractionated heparin (low certainty).
1 finding from 1 review
All‐cause mortality (5 days to 12 months) · people aged ≥ 18 years with a diagnosis of new or recurrent VTE
Subcutaneous unfractionated heparin showed no clear difference in all‐cause mortality (5 days to 12 months) compared with intravenous unfractionated heparin (low certainty).
1 finding from 1 review
Asymptomatic VTE at 3 months · people aged ≥ 18 years with a diagnosis of new or recurrent VTE
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Symptomatic recurrent VTE at 3 months · people aged ≥ 18 years with a diagnosis of new or recurrent VTE
Subcutaneous unfractionated heparin showed no clear difference in symptomatic recurrent VTE at 3 months compared with low molecular weight heparin (low certainty).
1 finding from 1 review
Symptomatic recurrent DVT at 3 months · people aged ≥ 18 years with a diagnosis of new or recurrent VTE
Subcutaneous unfractionated heparin showed no clear difference in symptomatic recurrent DVT at 3 months compared with low molecular weight heparin (low certainty).
1 finding from 1 review
Intervention not reported
Smoking uptake at longest · Children and adolescents aged 5 ‐ 18 years who were non‐smokers at baseline
The intervention showed no clear difference in smoking uptake at longest (low certainty).
1 finding from 1 review
Intervention not reported
Smoking uptake at longest · Children and adolescents aged 5 ‐ 18 years who were non‐smokers at baseline
It is very uncertain whether the intervention changes smoking uptake at longest (very low certainty).
1 finding from 1 review
Spasticity at up to 6 hours after treatment (measured by the Ashworth Scale, 0‐, with a higher score indicating greater spasticity) · children/young people aged 4‐18 years with traumatic brain injury and with 'mild to severe spastic tetraparesis' (weakness) in all limbs
1 finding from 1 review
Adverse events · children/young people aged 4‐18 years with traumatic brain injury and with 'mild to severe spastic tetraparesis' (weakness) in all limbs
1 finding from 1 review
Sensory functions and pain · children/young people aged 4‐18 years with traumatic brain injury and with 'mild to severe spastic tetraparesis' (weakness) in all limbs
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Neuromusculoskeletal and movement‐related functions post treatment (measured by range of movement) · children/young people aged 4‐18 years with traumatic brain injury and with 'mild to severe spastic tetraparesis' (weakness) in all limbs
1 finding from 1 review
General tasks and demands · children/young people aged 4‐18 years with traumatic brain injury and with 'mild to severe spastic tetraparesis' (weakness) in all limbs
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mobility · children/young people aged 4‐18 years with traumatic brain injury and with 'mild to severe spastic tetraparesis' (weakness) in all limbs
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Self‐care · children/young people aged 4‐18 years with traumatic brain injury and with 'mild to severe spastic tetraparesis' (weakness) in all limbs
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Inadequate oxygenation (SaO₂ < 90% on peripheral oxygen saturation) · adult patients (18 years of age and older) for positive pressure ventilation undergoing elective surgery
It is very uncertain whether proSeal changes inadequate oxygenation (SaO₂ < 90% on peripheral oxygen saturation) compared with classic laryngeal mask airway (LMA) (very low certainty).
1 finding from 1 review